HSC professor among international researchers using stem cells to combat COVID-19 pneumonia

By Diane Smith

Dr. Jin Covid Web

When news of the coronavirus emerged from Wuhan, China, Kunlin Jin, PhD, and a team of international researchers quickly joined forces to fight the mysterious disease.

Dr. Jin relied on his more than 20 years of knowledge about stem cells to work with an international team driven to save lives. He used the messaging app WeChat to bridge the distance between his laboratory at The University of North Texas Health Science Center at Fort Worth, and experts in China.

“A lot of people are trying find the answers,” said Dr. Jin, who spends most of his time working alongside graduate students on stem cell therapies to fight strokes at the HSC Institute for Healthy Aging.

Dr. Jin and his colleagues used a 21st century solution to address an unfolding pandemic. Instead of finding the next Tamiflu, they started testing whether stem cells can be used to boost a person’s immune system to ward off COVID-19 pneumonia.

Dr. Jin said early findings are promising, and their international effort to test this treatment continues as a long-term study with more patients in China.

“I am proud to be part of the team I work with to fight COVID-19,” Dr. Jin said. “Our study showed that intravenous infusion of clinical-grade human mesenchymal stem cells is a safe and efficient approach for treating patients with COVID-19 pneumonia, including in elderly patients displaying severe pneumonia.”

Working in real time

Dr. Jin and his colleagues worked in real time. He said they had a sense of urgency because the outbreak “posed great threats to global public health.”

As part of the experimental treatment, stem cells were injected intravenously into the bloodstream of seven patients in Beijing who were severely sick. Three patients were injected with a placebo, the study states.

The people tested were patients at YouAn Hospital in Beijing, Dr. Jin said. Testing began on Jan. 30, according to the study.

The seven patients who received stem cells were successfully treated and were discharged from the hospital within 14 days, Dr. Jin said. Of the patients who received the placebo, one died, one became severe and the third had Acute Respiratory Distress Syndrome (ARDS).

Before stem cells can be used in the United States to fight the virus, there would have to be clinical trials in this country and approval from the U.S. Food and Drug Administration.

The team’s findings will be included in the upcoming April 2020 issue of Aging and Disease (www.aginganddisease.org).” The article is titled: “Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.”

‘A desperate need for anything’

As international headlines about the virus evolved, research and clinical colleagues from several countries, including the United States, United Kingdom, South Korea, China and Russia pooled their expertise.

The team is made up of medical researchers who meet at conferences and often discuss science, aging and health-related issues. They work together as part of the International Society on Aging and Disease, which was founded by Dr. Jin.

When coronavirus strikes, it can result in a virus-induced cytokine storm – the term used when the immune system is so triggered that fluids fill the lungs and tissues are damaged.

“This is thought to be one of the main reasons why the COVID-19 pneumonia actually kills an individual – this storm of activity trying to fight the virus,” said David P. Siderovski, PhD, Professor and Chair Pharmacology & Neuroscience in HSC’s Graduate School of Biomedical Sciences.

“No specific drugs or vaccines are available to cure the patients with COVID-19 infection,” according to the journal article. “Hence, there is a large unmet need for a safe and effective treatment for COVID-19 infected patients, especially the severe cases.”

Additionally, finding antivirals for patients with COVID-19 is a difficult task, Dr. Siderovski said.

“When HIV broke in the 1980s, we scrambled to make AZT (azidothymidine),” he said, adding that researchers are trying different ideas to combat the virus. “There is a desperate need for anything – anything experimental, anything that could be tried off the shelf to address COVID-19 pneumonia.”

Recent News

2
  • Our People
|May 23, 2024

Empathy-driven leadership: Rylee Miller embarks on her journey to transform rural health care

At the age of 25, Rylee Miller is not just a Master in Health Administration student. Miller embodies the essence of a natural-born leader, driven by empathy and a relentless commitment to making a difference. Standing on the brink of a new chapter in her life, Miller is excited to leave a mark on r...
1
  • Our People
|May 23, 2024

Keeping Black mamas alive: TaKasha Davis Ehiogu is on a mission

TaKasha Davis Ehiogu, a 36-year-old Master in Public Health student, is on a mission to make childbirth safer for Black mothers. Her commitment stems from a deep-seated belief that birth in America should not pose any major risks for women, specifically women within a particular ethnic or socioecono...
  • Our People
|May 23, 2024

SBS grad is ready for success at the next level

When Jordan Easterling decided she wanted to go to medical school, she knew she needed excellent health and science training to help her get there. She found the Bachelor of Science in Biomedical Sciences at The University of North Texas Health Science Center at Fort Worth’s School of Biomedical ...
Ashley Gentry Headshot
  • Our People
|May 22, 2024

Faculty highlight: Ashley Gentry, Physician Assistant Studies

Ashley Gentry is an associate professor in The University of Health Science Center at Fort Worth’s Department of Physician Assistant Studies. She earned a Bachelor of Science in Biology from Dallas Baptist University and graduated from the HSC Physician Assistant Program in 2012 with a Master of P...